These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 20009855)

  • 1. A comparative analysis and systematic review of the wound-healing milieu: implications for body contouring after massive weight loss.
    Albino FP; Koltz PF; Gusenoff JA
    Plast Reconstr Surg; 2009 Nov; 124(5):1675-1682. PubMed ID: 20009855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discussion. A comparative analysis and systematic review of the wound-healing milieu: implications for body contouring after massive weight loss.
    Michaels J; Rubin JP
    Plast Reconstr Surg; 2009 Nov; 124(5):1683-1684. PubMed ID: 20009856
    [No Abstract]   [Full Text] [Related]  

  • 3. Increased matrix metalloproteinase-9 predicts poor wound healing in diabetic foot ulcers.
    Liu Y; Min D; Bolton T; Nubé V; Twigg SM; Yue DK; McLennan SV
    Diabetes Care; 2009 Jan; 32(1):117-9. PubMed ID: 18835949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endovascular treatment of aneurysms: healing mechanisms in a Swine model are associated with increased expression of matrix metalloproteinases, vascular cell adhesion molecule-1, and vascular endothelial growth factor, and decreased expression of tissue inhibitors of matrix metalloproteinases.
    Kadirvel R; Dai D; Ding YH; Danielson MA; Lewis DA; Cloft HJ; Kallmes DF
    AJNR Am J Neuroradiol; 2007 May; 28(5):849-56. PubMed ID: 17494655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of transforming growth factor-beta 1 by pancreatic stellate cells and its implications for matrix secretion and turnover in chronic pancreatitis.
    Shek FW; Benyon RC; Walker FM; McCrudden PR; Pender SL; Williams EJ; Johnson PA; Johnson CD; Bateman AC; Fine DR; Iredale JP
    Am J Pathol; 2002 May; 160(5):1787-98. PubMed ID: 12000730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ratios of activated matrix metalloproteinase-9 to tissue inhibitor of matrix metalloproteinase-1 in wound fluids are inversely correlated with healing of pressure ulcers.
    Ladwig GP; Robson MC; Liu R; Kuhn MA; Muir DF; Schultz GS
    Wound Repair Regen; 2002; 10(1):26-37. PubMed ID: 11983004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Matrix Metalloproteinases MMP-2 and MMP-9, Their Inhibitors TIMP-1 and TIMP-2, Vascular Endothelial Growth Factor and sVEGFR-2 as Predictive Markers of Ischemic Retinopathy in Patients with Systemic Sclerosis-Case Series Report.
    Waszczykowska A; Podgórski M; Waszczykowski M; Gerlicz-Kowalczuk Z; Jurowski P
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33218057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TIMP-1, MMP-2, MMP-9, and PIIINP as serum markers for skin fibrosis in patients following severe burn trauma.
    Ulrich D; Noah EM; von Heimburg D; Pallua N
    Plast Reconstr Surg; 2003 Apr; 111(4):1423-31. PubMed ID: 12618601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Downregulation of vascular matrix metalloproteinase inducer and activator proteins in hypertensive patients.
    Ergul A; Portik-Dobos V; Hutchinson J; Franco J; Anstadt MP
    Am J Hypertens; 2004 Sep; 17(9):775-82. PubMed ID: 15363819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MMP-8 overexpression and persistence of neutrophils relate to stress-impaired healing and poor collagen architecture in mice.
    Gajendrareddy PK; Engeland CG; Junges R; Horan MP; Rojas IG; Marucha PT
    Brain Behav Immun; 2013 Feb; 28():44-8. PubMed ID: 23103444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of vascular-endothelial growth factor, matrix metalloproteinases and tissue inhibitors of metalloproteinases in primary breast cancer.
    Jobim FC; Xavier NL; Uchoa DM; Cruz DB; Saciloto M; Chemello N; Schwartsmann G
    Braz J Med Biol Res; 2009 Oct; 42(10):979-87. PubMed ID: 19787153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic changes in the expression of matrix metalloproteinases and their inhibitors, TIMPs, during hepatic fibrosis induced by alcohol in rats.
    Xu GF; Li PT; Wang XY; Jia X; Tian DL; Jiang LD; Yang JX
    World J Gastroenterol; 2004 Dec; 10(24):3621-7. PubMed ID: 15534918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MMP-7 and TIMP-1, new targets in predicting poor wound healing in apical periodontitis.
    Letra A; Ghaneh G; Zhao M; Ray H; Francisconi CF; Garlet GP; Silva RM
    J Endod; 2013 Sep; 39(9):1141-6. PubMed ID: 23953287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of differential expression of extracellular matrix metalloproteinase inducer, matrix metalloproteinase-2, tissue inhibitor of matrix metalloproteinase-2 and PDGF-AA on the chronicity of venous leg ulcers.
    Mwaura B; Mahendran B; Hynes N; Defreitas D; Avalos G; Adegbola T; Adham M; Connolly CE; Sultan S
    Eur J Vasc Endovasc Surg; 2006 Mar; 31(3):306-10. PubMed ID: 16169261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging.
    Baker EA; Bergin FG; Leaper DJ
    Br J Surg; 2000 Sep; 87(9):1215-21. PubMed ID: 10971431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 in inflammation-induced corneal neovascularization.
    Ma DH; Chen JK; Kim WS; Hao YX; Wu HC; Tsai RJ; Hwang DG; Zhang F
    Ophthalmic Res; 2001; 33(6):353-62. PubMed ID: 11721189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Profile of Metalloproteinases and Their Association with Inflammatory Markers in Pleural Effusions.
    Teixeira LR; Dias MB; Sales RK; Antonangelo L; Alvarenga VA; Puka J; Marchi E; Acencio MM
    Lung; 2016 Dec; 194(6):1021-1027. PubMed ID: 27677622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma.
    Manenti L; Paganoni P; Floriani I; Landoni F; Torri V; Buda A; Taraboletti G; Labianca R; Belotti D; Giavazzi R
    Eur J Cancer; 2003 Sep; 39(13):1948-56. PubMed ID: 12932675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imbalances between matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs) in maternal serum during preterm labor.
    Tency I; Verstraelen H; Kroes I; Holtappels G; Verhasselt B; Vaneechoutte M; Verhelst R; Temmerman M
    PLoS One; 2012; 7(11):e49042. PubMed ID: 23145060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in sera and tissue of patients with Dupuytren's disease.
    Ulrich D; Hrynyschyn K; Pallua N
    Plast Reconstr Surg; 2003 Oct; 112(5):1279-86. PubMed ID: 14504511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.